Post–Total Thyroidectomy Surveillance in Differentiated Thyroid Cancer with Undetectable Thyroglobulin and Positive Anti-Thyroglobulin Antibodies
Serum thyroglobulin (Tg) and anti-thyroglobulin antibodies (TgAb) should be used together for biochemical surveillance after total thyroidectomy. [1] Neck ultrasound is the primary surveillance modality when Tg is uninterpretable due to TgAb positivity. [1]
Levothyroxine (TSH) Targets and Ongoing Thyroid Hormone Management
Long-term TSH suppression below the reference range is not suggested for patients with low- or intermediate-risk disease who have no evidence of biochemical or structural recurrence. [1] TSH goals should be reassessed over time based on risk and response to therapy. [1]
Biochemical Monitoring Strategy
Serum Tg should be measured using an assay calibrated to BCR-457, and TgAb should be quantitatively measured with every Tg measurement. [1] During initial follow-up, Tg on thyroid hormone therapy should be measured every 6–12 months. [1] More frequent serum Tg measurements are appropriate for ATA intermediate-high or high-risk patients. [1]
Imaging Surveillance With Negative Ultrasound
Neck ultrasound is recommended 6–12 months after completion of initial therapy to evaluate the thyroid bed and cervical lymph node compartments. [1] After that first post-therapy ultrasound, the timing and frequency of additional neck ultrasound are informed by risk for residual or recurrent disease and response to therapy. [1] When Tg (or TgAb) levels rise after total thyroidectomy and cervical ultrasound demonstrates no structural disease or only minimal tumor burden, cross-sectional imaging of common metastatic sites should be performed. [1]
Interpreting Positive Anti-Thyroglobulin Antibodies With Undetectable Thyroglobulin
In patients with circulating TgAb, trends of serial TgAb using the same assay should be used for monitoring, because Tg immunoassays may be affected by TgAb. [1] Current Tg immunometric assays and related methods should not be relied upon solely to monitor patients with TgAb positivity. [1] The primary modality in TgAb-positive patients is imaging surveillance. [1]
De-escalation of Surveillance Intensity
For low-risk differentiated thyroid cancer treated with total thyroidectomy plus radioactive iodine who have a sustained excellent response 5–8 years after initial therapy, routine ultrasound can be discontinued and follow-up can be performed with biochemical markers alone every 1–2 years. [1] For low-risk differentiated thyroid cancer treated with total thyroidectomy without radioactive iodine, surveillance ultrasound intervals for an excellent response are consistent with every 1–3 years for 5–8 years, followed by discontinuation unless Tg rises or TgAb becomes newly detectable. [1]
Practical Follow-Up Plan for the Presented Clinical Scenario
Serum Tg and TgAb should be repeated on thyroid hormone therapy with the same laboratory/assay where feasible to assess Tg remains undetectable and to determine whether TgAb levels are stable, declining, or rising. [1] Neck ultrasound should follow the 6–12 month post–initial therapy surveillance timeframe and thereafter be individualized to risk and biochemical response. [1] No additional empiric imaging is indicated based on a single negative ultrasound study in the setting of undetectable Tg with TgAb positivity; surveillance should instead be driven by TgAb trend and ultrasound findings. [1] If TgAb levels are rising over time with continued negative ultrasound findings, additional evaluation with cross-sectional imaging of common metastatic sites should be pursued. [1]
Surveillance Endpoints Supporting Ongoing Reassurance
A stable or declining TgAb trend with persistently negative imaging supports a favorable biochemical trajectory during follow-up. [1] Escalation is supported by rising TgAb (with rising trend, not a single value) together with negative or minimal findings on cervical ultrasound. [1] Long-term de-escalation is supported only after a sustained excellent response and prolonged follow-up duration for low-risk disease. [1]